The Deep Tech Decade: Cantos Chats Where Deep Tech is Headed in 2022

The Deep Tech Decade: Cantos Chats Where Deep Tech is Headed in 2022
Near Frontier
The Deep Tech Decade: Cantos Chats Where Deep Tech is Headed in 2022

Feb 09 2022 | 00:29:53

/
Episode 3 February 09, 2022 00:29:53

Show Notes

Cantos analysts Amee and Andrew dive into their top predictions for what deep tech might see in 2022. 

Shownotes:

  1. Our 2022 predictions blog post
  2. Trailblazer's List by Mina Fahmi: https://trailblazerlist.xyz/
  3. Loonshots by Safi Bahcall
  4. Speed & Scale by John Doerr
  5. New funding models in biotech
  6. Nuclear energy blog post

Other Episodes

March 16, 2022

Organ Printing with Melanie Matheu of Prellis Biologics

We talk to Prellis Biologics founder Melanie Matheu about bioprinting organs with Prellis' holographic laser technology, using bioprinted lymph node organoids for antibody discovery, and Melanie's advice for new bio founders with regards to choosing focus and setting early partnerships.  Note: We discuss the January 2022 pig-to-human heart transplant at 13:45. This episode was recorded before we learned that the recipient of the transplant has since passed away.  Get in touch with Prellis— Prellis Twitter Melanie's Twitter Prellis website ...

Play

00:38:29

February 22, 2022

Synthetic Biology and Biomanufacturing with Joshua Britton from Debut Biotech

Today we're joined by Dr. Joshua Britton, founder and CEO of Debut Biotech, a cell-free biomanufacturing company. Josh gives us a crash course on synthetic biology and biomanufacturing, walking us through the various methods and promise of this industry that may very well shift industrial production away from fossil fuels. We also get into some of the founding story of Debut, including how Cantos' investment in Debut came to be...hint: it had to do with a cold message.  Shownotes: Power: Limits and Prospects foor Human Survial by Richard Heinberg McKinsey report on synthetic biology Debut Biotech on Twitter ...

Play

00:56:28

January 25, 2022

RNA Delivery with Anna Perdrix and George Foot of Sixfold Bioscience

Today we're joined by Anna Perdrix Rossell and George Foot of Sixfold Bioscience, co-founders of Sixfold Bioscience, a UK based biotech company using computation and advanced chemistry to engineer highly programmable constructs that make the delivery of RNA therapeutics predictable and precise. Sixfold's technology expands the purview of RNA therapeutics from vaccines to all diseases, starting with cancer. In our conversation, we discuss the challenge of RNA delivery, what it's like starting a biotech company totally from scratch (no academic spinout or venture incubation), how to hire a diverse team, and promising areas of biotechnology.    Shownotes: Get in touch with the Sixfold team: Sixfold Bioscience; George Foot; Anna Perdrix Interested in joining the team? Check out open roles here In this episode, we cover:  Sixfold Bioscience and challenges with RNA delivery  How George and Anna started Sixfold Switching between an academia and entrepreneurship mindset Building a biotech totally from scratch Twitter debate—founder led bio vs venture incubation  Building a diverse (majority women!) team and tips for recruitment Sixfold's big vision Broader trends to be excited about in biotech and deep tech ...

Play

00:43:57